Part of the Contributions to Economics book series (CE)


This chapter presents an overview of the Indian Pharmaceutical Industry and traces its evolution and growth. From the review of policies and the analysis of the aggregate data, we conclude that the patent law of 1970 and the knowl-edge spillover from the public sector units provided the necessary impetus for the growth of the industry. Presently, the structure of industry looks highly competi-tive with the top twenty firms capturing about eighty percent of the market and negligible barrier to entry. However, contrary to the conventional economic wis-dom evidence also suggests that it is one of the most profitable industries. The co-existence of low concentration and high profit earning that is observed can be attributed to firm specific factors like its efficiency, returns from R&D, marketing related outlays and earning from global market.


Foreign Direct Investment Foreign Firm Intellectual Property Right Technological Frontier Malmquist Productivity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Acemoglu, D, J Linn (2004) Market size in innovation: theory and evidence from the pharmaceutical industry, Working Paper, MIT, Department of EconomicsGoogle Scholar
  2. Aradhana (2007) The Indian pharmaceutical industry. In: Kumar N, Joseph KJ (eds) International competitiveness and knowledge based industries in India. Oxford University Press, New DelhiGoogle Scholar
  3. Bain J (1956) Barrier to new competition. Harvard University Press, Cambridge, MAGoogle Scholar
  4. Bain J (1951) Relation of profit rate to industry concentration: American manufacturing, 1936–1940. Quaterly Journal of Economics 65:293–324CrossRefGoogle Scholar
  5. Barney JB (1991) Firm resources and sustained competitive advantage. Journal of Management 17(1):99–120CrossRefGoogle Scholar
  6. Bhadhuri S, Ray AS (2001) R&D and technological learning in Indian industry: econometric estimation of the research production function. Oxford Development Studies 29(2):101–123Google Scholar
  7. Bhandari AK, Ray SC (2007) Technical efficiency in the Indian textiles industry: a nonparametric analysis of firm-level data. University of Connecticut Department of Economics Working Paper Series 2007–49Google Scholar
  8. Bottazzi G, Dosi G, Lippi M, Pammolli F, Riccaboni M (2002) Innovation and corporate growth in the evolution of the drug industry. International Journal of Industrial Organization 19:1161–87CrossRefGoogle Scholar
  9. Calfee JE (2002) Public policy issues in direct-to-consumer advertising of prescription drugs. Journal of Public Policy & Marketing 21:174–93CrossRefGoogle Scholar
  10. Chaudhuri S (1999) Growth and structural changes in the pharmaceutical industries in India, Working paper series No.356, IIM: Indian Institute of Management, CalcuttaGoogle Scholar
  11. Chaudhuri S, Goldberg P, Jha P (2006) Estimating the effect of global patent protection in pharmaceuticals: a case study of quinolones in India. American Economic Review 96(5):1477–1514CrossRefGoogle Scholar
  12. Church J, Ware R (2000) Industrial organization: a strategic approach. McGraw Hill, New YorkGoogle Scholar
  13. Cockburn I, Henderson RM (2000) Publicly funded science and the productivity of the pharmaceutical industry. In: Jaffe A, Lerner J, Stern S (eds) Innovation policy and the economy, vol I. MIT Press, Cambridge, MA, pp 1–34Google Scholar
  14. Cockburn IM, Henderson RM (1998) Absorptive capacity, coauthoring behavior, and the organization of research in drug. Journal of Industrial Economics 46(2):157–82CrossRefGoogle Scholar
  15. Comanor WS (1967) Market structure, product differentiation and industrial research. Quarterly Journal of Economics 81:639–51CrossRefGoogle Scholar
  16. Coscelli A (2000) The importance of doctor’s and patient’s preference in the Prescription DecisionGoogle Scholar
  17. Cubbin J, Geroski PA (1987) The convergence of profits in the long run: inter-firm and inter-industry comparisons. Journal of Industrial Economics 35:427–42CrossRefGoogle Scholar
  18. Danzon PM, Wang YR, Wang L (2005) The impact of price. Health Economics 14(3):269–292CrossRefGoogle Scholar
  19. Danzon PM (1997) Price discrimination for pharmaceuticals: welfare effects in the US and the EU. International Journal of the Economics of Business 4(3):301–321CrossRefGoogle Scholar
  20. Danzon PM, Chao LW (2000) Does regulation drive out competition in pharmaceutical markets? Journal of Law & Economics 43(2):311–357CrossRefGoogle Scholar
  21. Demsetz H (1973a) The market concentration doctrine. American Enterprises Institution, Washington, DCGoogle Scholar
  22. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10:107–142CrossRefGoogle Scholar
  23. Ellison SF, Cockburn I, Griliches Z, Hausman J (1997) Characteristics of demand for Pharmaceutical products: an examination of four cephalosporins. The Rand Journal of Economics 28(3):426–446CrossRefGoogle Scholar
  24. Ernst and Young Report (2005) Unveiling India’s pharmaceutical futureGoogle Scholar
  25. Federation of Indian Chambers of Commerce and Industry (FICCI) (2005) Competitiveness of the Indian pharmaceutical industry in the new product patent regime. FICCI Report for national manufacturing competitiveness council (NMCC), New Delhi. Available at
  26. Findlay SD (2001) Direct-to-consumer promotion of prescription drugs. Economic implication for patient, payers and providers. Pharmacoeconomics 19(2):109–119CrossRefGoogle Scholar
  27. Fink C (2002) How stronger patent protection in India might affect the behavior or transnational pharmaceutical industries. Development Research Group no. 219, The World BankGoogle Scholar
  28. Gambardella A (1992) Competitive advantages from in-house scientific research: the US pharmaceutical industry in the 1980s. Research Policy 21:391–407CrossRefGoogle Scholar
  29. Govindaraj R, Chellaraj G (2002) The Indian pharmaceutical sector: issues and options for health sector reform. World Bank Discussion Paper No. 437Google Scholar
  30. Grabowski H, Vernon JM (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug Act. Journal of Law and Economics 35:331–340CrossRefGoogle Scholar
  31. Grabowski HG, Vernon JM (1981) The determinants of R&D expenditures. In: Helms RB (ed) Drugs and health. AEI Press, WashingtonGoogle Scholar
  32. Grabowski H, Vernon J (1987) Pioneers, imitators, and generics: a simulation model of Schumpeterian competition. Quarterly Journal of Economics 102(3):491–525CrossRefGoogle Scholar
  33. Hurwitz MA, Caves RE (1988) Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. Journal of Law and Economics 31(2):299–320CrossRefGoogle Scholar
  34. Kanavos P (2001) Overview of pharmaceutical pricing and reimbursement regulation. London School of Economics, LondonGoogle Scholar
  35. KPMG (2006) ‘The Indian Pharmaceutical Industry: Collaboration for Growth’.Google Scholar
  36. Kumar N and J P Pradhan, (2004) Economic Reforms, WTO and Indian Drugs and Pharmaceutical Industry, CMDR Monograph Series No-42: Centre For Multi-Disciplinary Development Research, Dharwad.Google Scholar
  37. Kwong WJ, Norton E (2007) The effect of advertising on pharmaceutical innovation. Review of Industrial Organization 31(3):221–236CrossRefGoogle Scholar
  38. Kyle MK (2003) Pharmaceutical Price Controls and Entry Strategies. Fuqua School of Business, Duke University, Working PaperGoogle Scholar
  39. Kyle MK (2004) The Role of Firm Characteristics in Pharmaceutical Product Launches. Fuqua School of Business, Duke University, Working PaperGoogle Scholar
  40. Lalitha,N (2002), Indian pharmaceutical industry in WTO regime: A SWOT Analysis Economic and Political Weekly August 24.Google Scholar
  41. Lanjouw J O, (2005) "Patents, Price Controls, and Access to New Drugs: How Policy," NBER Working Papers 11321, National Bureau of Economic Research.Google Scholar
  42. Lanjouw, J.O. (1997) ‘The Introduction of Product Patents in India: 'Heartless Exploitation of the Poor and Suffering?’, Economic Growth Center Discussion Paper, no 775, Yale University. 1–56.Google Scholar
  43. Leffler KB (1981) Persuasion or Information? The Economics of Prescription Drugs Advertising. Journal of Law and Economics 24(1):45–74CrossRefGoogle Scholar
  44. Mansfield E (1968) Industrial Research and Development Expenditure: Determinants, Prospects, and Relation of Size of Firm and Inventive Output. Journal of Political Economy 72(4):290–311Google Scholar
  45. Mansfield E (1985) How rapidly does new Industrial technology leak out? Journal of Industrial Economics 34(2):217–223CrossRefGoogle Scholar
  46. Mansfield E (1986) Technological change and International diffusion of technology: a survey of findings in McFtriedge, D (ed) Technological Change in Canadian Industry. University of Toronto Press, Toronto, pp 77–99Google Scholar
  47. Mariani M (2007) “Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals” in Knowledge Accumulation and Industry Evolution: The case of Pharma-Biotech edited by Mariani Mazzucato and Giovanni Dosi Cambridge University Press, Cambridge.Google Scholar
  48. Marjit S, Beladi H (1998) Product versus Process Patents. Journal of Policy Modeling 20(2):193–199CrossRefGoogle Scholar
  49. Mason, E (1939) ‘Price and production policies of large-scale enterprises’, American economic Review 29(Suppl.29) pp 61–74.Google Scholar
  50. Mueller D (1986) Profits in the Long Run. New York, OxfordCrossRefGoogle Scholar
  51. Mueller, D (1990) ‘The Dynamics of Company Profits’, Cambridge UK.Google Scholar
  52. Narayana PL (1984) The Indian Pharmaceutical Industry: Problems and Prospects. New Delhi, National Council of Applied Economic Research (NCEAR)Google Scholar
  53. Peltzman S (1973) An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments. Journal of Political Economics 81(5):1049–91CrossRefGoogle Scholar
  54. Peltzman S (1974) ‘Regulation of pharmaceutical innovation: The 1962 amendments’ Washington. American Enterprise Institute, DCGoogle Scholar
  55. Pharma Review, (2005) The Indian Pharma Reference Guide, August Konsposh Publication New Delhi.Google Scholar
  56. Pradhan J P and N Kumar (2007) ‘Knowledge based export in India: A Firm level Analysis of Determinants’in N Kumar and K J Joseph (edited) International Competitiveness & Knowledge based Industry New Delhi 53–96.Google Scholar
  57. Pradhan JP (2002a) FDI spillover and local productivity growth: evidence from Indian pharmaceutical industry. Artha-vijanana Vol XLIV 3–4:21–34Google Scholar
  58. Pradhan JP (2002b) Liberalization Firm Size and R&D Performance. A Firm Level Study of Indian Pharmaceutical Industry. Journal of Indian School of Political Economy Vol 14(2):54–79Google Scholar
  59. Raizada B (2002) ‘Intellectual Property, Technology and Policy Framework – Experience of India in the Pharmaceutical Sector’ Document prepared for the WIPO national Seminar on Industrial Property and the Patent Cooperation Treaty (PCT).Google Scholar
  60. Ramani l (2002) ‘Who is interested in Biotech? R&DError! Bookmark not defined. strategiesError! Bookmark not defined., knowledge base and market sales of Indian biopharmaceutical firmsError! Bookmark not defined.Research Policy Error! Bookmark not defined. Vol 31, 381–398Google Scholar
  61. Reiffen D, Ward M (2005) Generic Drug Industry Dynamics. Review of Economics and Statistics 87:37–49CrossRefGoogle Scholar
  62. Rizzo AJ (1999) Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs. Journal of Law and Economics 42(1):89–116CrossRefGoogle Scholar
  63. Robert JM, Tybout RJ (1996) Industrial Evolution in Developing Countries: Micro Patterns of Turnover. Oxford University Press, New York, Productivity and Market StructureGoogle Scholar
  64. Röller, L H and B Sinclair-Desgagn´e (1996) ‘On the Heterogeneity of Firms’, European Economic Review, 40, 531–539Google Scholar
  65. Sachverständigenrat Gesundheit (2005), des Sachverständigenrates zur Begutachtung der Entwicklung im Gesundheitswesen: Koordination und Qualität im Gesundheitswesen, BerlinGoogle Scholar
  66. Scherer FM and D Ross (1990), Industrial Market Structure and Economic performance (3rd edn) Huognton Mifflin: Boston, MA.Google Scholar
  67. Scherer, F M (1993) ‘Pricing, profits, and technological progress in the pharmaceutical industry’, Journal of Economic Perspectives Vol7 (3), 95–115.Google Scholar
  68. Schwatrzman D (1976a) ‘Innovations in the Pharmaceutical Industry’ Baltimore John Hopkins University.Google Scholar
  69. Schwatrzman D (1976b) ‘Pharmaceutical R&D Expenditure and Rates of Returns’ in Drugs Development and Marketing R B Helm(s) Edited American Enterprise Institute Washington D C.Google Scholar
  70. Schweitzer SO (1997) Pharmaceutical Economics and Policy, Oxford University Press. University Press, New YorkGoogle Scholar
  71. Scott M, Fiona M (2000) Barriers to entry, brand. International Journal of Industrial Organization 18(7):1085–1104CrossRefGoogle Scholar
  72. Scott-Morton, F. (1999) “Entry Decision in the Generic Drug Industry,” The Rand Journal of Economics, XXX 421–440Google Scholar
  73. Tybout, J. (2000) ‘Manufacturing firms in developing countries: How well do they do and why ?’ Journal of Economic Literature Vol XXXVIII pp 11–44.Google Scholar
  74. Watal J (2000) Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPS Agreement. The World Economy 23(5):733–752CrossRefGoogle Scholar
  75. Wiggins SN (1981) Product Quality Regulation and New Drug Introductions: Some New Evidence From the 1970s. The Review of Economics and Statistics 63(4):615–619CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Centre De Sciences Humaines (CSH)New DelhiIndia

Personalised recommendations